Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline reports positive data for new Cervarix dosing regimen

GlaxoSmithKline reports positive data for new Cervarix dosing regimen

5th November 2013

GlaxoSmithKline has announced phase III clinical trial data showing the efficacy of a new dosing regimen for its cervical cancer vaccine Cervarix.

The human papillomavirus vaccine was trialled in a two-dose schedule among girls between the ages of nine and 14, with the regimen providing an immunogenicity matching the currently licensed three-dose schedule in 15 to 25-year-olds.

These results, which were presented at the EUROGIN conference in Florence earlier this week, corroborate the findings of the earlier HPV-048 proof of concept study and confirm the safety and efficacy of this administration method.

Currently, Cervarix is only approved in Europe for use in females from the age of nine years according to a three-dose schedule, but GlaxoSmithKline has already applied for its licence to be updated to include the two-dose option.

Data from this new phase III study will help to support the application.

This comes after the company announced last month that it will be filing for EU approval of its groundbreaking new malaria vaccine candidate RTS,S based on its success in phase III trials.ADNFCR-8000103-ID-801657051-ADNFCR

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.